Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
Clinical trial NCT06893354 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06893354
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-10
- Primary completion
- 2027-07-20
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.